Developer docs
API playgroundTry for free, no card

Search company profiles

Red Arrow Therapeutics

Full company profile

uuid0003966

Namestring
Red Arrow Therapeutics
Legal namestring
Red Arrow Therapeutics, Inc.
Websiteurl
redarrowtx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Red Arrow Therapeutics is a preclinical-stage biotechnology company developing a proprietary pH-responsive nanopolymer drug delivery platform for biologic payloads. The platform encapsulates biologics — including cytokines, peptides, and antibodies (cationic to anionic proteins) — into micelles that remain inert in circulation and release their payload in response to the acidic tumor microenvironment, enabling on-target, on-tumor delivery with reduced off-target toxicity. The lead pipeline asset is a nanopolymer formulation of the pro-inflammatory cytokine IL-12 for solid tumors, positioned as a combination therapy with checkpoint inhibitors for the roughly 80% of solid tumor patients who do not respond to current immunotherapy. Additional polymer-drug conjugate programs are in discovery.

The company was founded in August 2021 as a spin-off from Prof. Horacio Cabral's laboratory at the University of Tokyo, co-founded by Cabral and Takuya Miyazaki, PhD. It has since relocated its corporate headquarters to Cambridge, Massachusetts while maintaining wet-lab operations in Tokyo, and appointed Philipp Steiner, PhD as Chief Scientific Officer in March 2026. Capitalization totals approximately $5.5–7M in seed equity from a Japanese university-affiliated VC syndicate (UTEC, BNV, KII, OUVC), supplemented by up to ~$47.4M in potential non-dilutive Japanese government funding (AMED Drug Discovery Venture Ecosystem Enhancement Program and NEDO STS).

Red Arrow is pre-revenue with no commercial products and no disclosed pricing. Its intended business model is eventual licensing, co-development partnerships, or acquisition by larger pharmaceutical companies for clinical development and commercialization of its pipeline assets. The team is small (fewer than 10 research staff per the company's job posting), with no commercial sales organization, and its current visibility derives from accelerator participation (UC Berkeley SkyDeck, MassChallenge) and Japanese government grant awards rather than commercial traction.

Short descriptiontext

Red Arrow Therapeutics is a preclinical biotech developing a proprietary pH-responsive nanopolymer platform to deliver cytokines and other biologics to solid tumors, with an IL-12 lead program aimed at the 80% of solid tumor patients who do not respond to checkpoint inhibitors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nanomedicine drug delivery, polymer drug conjugates, cancer immunotherapy platform, biologic encapsulation technology, cytokine delivery oncology
Industry3 codes
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Nanomedicine / Drug Delivery
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development
TypeLicensing Royalties
Description

Pre-revenue company developing nanomedicine drug delivery platform for cancer treatment. Revenue model would eventually come from licensing, co-development partnerships, or eventual product sales through pharmaceutical partnerships. Currently in preclinical development stage with research funded by grants.

redarrowtx.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Red Arrow Therapeutics develops a proprietary pH-responsive nanopolymer drug-delivery platform that encapsulates and releases biologics (including cytokines, small peptides, full-chain antibodies, and cationic/anionic proteins) specifically at tumor microenvironments. Its first pipeline asset delivers pro-inflammatory cytokine IL-12 for solid tumors and is in preclinical development, with additional polymer-drug conjugate cancer drugs in discovery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Cytokine-loaded nanopolymer micelles can target the 80% of solid tumor patients who don't respond to checkpoint inhibitors
Product overview1 text field

Red Arrow Therapeutics operates a single integrated platform business model centered on its proprietary Nanopolymer Drug-Delivery System. The core platform enables pH-responsive encapsulation and release of biologic payloads, particularly cytokines for cancer immunotherapy. The first pipeline product is IL-12 loaded nanopolymer micelles for solid tumor treatment, currently in preclinical stage, with additional polymer-drug conjugate cancer drugs in discovery.

Product and service2 records
1IL-12 Loaded Nanopolymer Micelles
CategoryOncology pipeline asset / polymer-drug conjugate
Description

Red Arrow's lead pipeline product: a polymer-drug conjugate that systemically delivers pro-inflammatory cytokine IL-12 via nanopolymer micelles to the solid tumor microenvironment, where the cytokine is released to recruit immune cells and induce cancer cell death. Intended for combination therapy with checkpoint inhibitors for solid tumor patients. Currently in preclinical stage.

2Polymer-Drug Conjugate Cancer Drugs (Pipeline)
CategoryOncology pipeline / polymer-drug conjugates
Description

Pipeline of polymer-drug conjugate cancer drugs developed using Red Arrow's proprietary nanopolymer platform for specific on-target on-tumor delivery and reduced on-target off-tumor toxicity. Follow-up pipeline efforts are currently in discovery phase.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-01
Description

Accepted into U.S. Early Stage Growth Cohort program - prestigious startup accelerator focused on early stage companies.

2UC Berkeley SkyDeck
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-01
Description

Selected to join SkyDeck Accelerator Cohort Program with 1.5% acceptance rate worldwide. Dr. Takuya Miyazaki presented at Demo Day Berkeley SKYDECK in April 2023. Previous investment from SkyDeck included in total funding.

redarrowtx.com
3University of Tokyo
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Spin-out from University of Tokyo's Cabral Lab in 2021. Laboratory remains closely associated with the University of Tokyo. Technology developed by Prof. Dr. Horacio Cabral from University of Tokyo.

redarrowtx.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Selecta Biosciences
TypeDirect peer
Description

Developed synthetic nanoparticle immunotherapies including tolerogenic and immunogenic vaccines, with overlapping focus on programming immune responses using nanoparticle carriers.

2Codiak BioSciences
TypeDirect peer
Description

Developed engineered exosome-based platforms for delivery of biologics including cytokines, the closest mechanistic analogue to Red Arrow's biologic-loaded nanocarrier approach.

TypeDirect peer
Description

Clinical-stage nanomedicine company developing nanoparticle-based cancer therapeutics. Directly comparable as a nanoparticle-platform oncology company, though at a more advanced clinical stage.

4NanoCarrier Co., Ltd.
TypeDirect peer
Description

Japanese specialty pharmaceutical company developing micellar nanoparticle drug delivery systems for cancer and other diseases. Closest geographic and technical peer in the Japanese nanomedicine ecosystem.

TypeDirect peer
Description

Developed nanoliposomal oncology therapeutics (e.g., Onivyde) and built a pipeline around nanoparticle-encapsulated biologics for solid tumors, a comparable biologic-delivery strategy.

TypeEmerging player
Description

Develops lipid nanoparticle (LNP) delivery technology used across nucleic-acid and biologic therapeutics, including for partners in oncology. Comparable as a delivery-platform peer at a more commercial stage.

TypeBroad incumbent
Description

Clinical-stage biotech using lipid nanoparticle delivery platforms for nucleic-acid and protein-based therapeutics, with broader pipeline and manufacturing footprint.

TypeDirect peer
Description

Pioneered targeted polymeric nanoparticle drug delivery for oncology, including programs delivering cytotoxics and other biologics. Closely aligned platform approach despite corporate restructuring.

9PsiOxus Therapeutics
TypeEmerging player
Description

Developed tumor-targeted immunotherapies including cytokine-armed oncolytic viruses, a comparable strategy of localizing potent immunomodulators to the tumor microenvironment.

10CytImmune Sciences
TypeDirect peer
Description

Developed tumor-targeted gold nanoparticle delivery of TNF and other cytokines to solid tumors, directly comparable in payload (cytokines) and tumor-targeting mechanism.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Red Arrow Therapeutics

Oncology Nanomedicine / Drug Deliveryredarrowtx.com

Red Arrow Therapeutics is a preclinical biotech developing a proprietary pH-responsive nanopolymer platform to deliver cytokines and other biologics to solid tumors, with an IL-12 lead program aimed at the 80% of solid tumor patients who do not respond to checkpoint inhibitors.

What Red Arrow Therapeutics does

Red Arrow Therapeutics is a preclinical-stage biotechnology company developing a proprietary pH-responsive nanopolymer drug delivery platform for biologic payloads. The platform encapsulates biologics — including cytokines, peptides, and antibodies (cationic to anionic proteins) — into micelles that remain inert in circulation and release their payload in response to the acidic tumor microenvironment, enabling on-target, on-tumor delivery with reduced off-target toxicity. The lead pipeline asset is a nanopolymer formulation of the pro-inflammatory cytokine IL-12 for solid tumors, positioned as a combination therapy with checkpoint inhibitors for the roughly 80% of solid tumor patients who do not respond to current immunotherapy. Additional polymer-drug conjugate programs are in discovery.

The company was founded in August 2021 as a spin-off from Prof. Horacio Cabral's laboratory at the University of Tokyo, co-founded by Cabral and Takuya Miyazaki, PhD. It has since relocated its corporate headquarters to Cambridge, Massachusetts while maintaining wet-lab operations in Tokyo, and appointed Philipp Steiner, PhD as Chief Scientific Officer in March 2026. Capitalization totals approximately $5.5–7M in seed equity from a Japanese university-affiliated VC syndicate (UTEC, BNV, KII, OUVC), supplemented by up to ~$47.4M in potential non-dilutive Japanese government funding (AMED Drug Discovery Venture Ecosystem Enhancement Program and NEDO STS).

Red Arrow is pre-revenue with no commercial products and no disclosed pricing. Its intended business model is eventual licensing, co-development partnerships, or acquisition by larger pharmaceutical companies for clinical development and commercialization of its pipeline assets. The team is small (fewer than 10 research staff per the company's job posting), with no commercial sales organization, and its current visibility derives from accelerator participation (UC Berkeley SkyDeck, MassChallenge) and Japanese government grant awards rather than commercial traction.

Red Arrow Therapeutics firmographics

Firmographics
Name
Red Arrow Therapeutics
Legal name
Red Arrow Therapeutics, Inc.
Website
https://redarrowtx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Red Arrow Therapeutics is a preclinical biotech developing a proprietary pH-responsive nanopolymer platform to deliver cytokines and other biologics to solid tumors, with an IL-12 lead program aimed at the 80% of solid tumor patients who do not respond to checkpoint inhibitors.
Ownership category
akta.pro rank

Red Arrow Therapeutics industry classification

Industry
Product category
Oncology Nanomedicine / Drug Delivery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Nanomedicine drug delivery
  • Polymer drug conjugates
  • Cancer immunotherapy platform
  • Biologic encapsulation technology
  • Cytokine delivery oncology

Where Red Arrow Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Red Arrow Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Pharmaceutical Development: Pre-revenue company developing nanomedicine drug delivery platform for cancer treatment. Revenue model would eventually come from licensing, co-development partnerships, or eventual product sales through pharmaceutical partnerships. Currently in preclinical development stage with research funded by grants.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Red Arrow Therapeutics product offering

Product offering

Core offering

Red Arrow Therapeutics develops a proprietary pH-responsive nanopolymer drug-delivery platform that encapsulates and releases biologics (including cytokines, small peptides, full-chain antibodies, and cationic/anionic proteins) specifically at tumor microenvironments. Its first pipeline asset delivers pro-inflammatory cytokine IL-12 for solid tumors and is in preclinical development, with additional polymer-drug conjugate cancer drugs in discovery.

Product overview

Red Arrow Therapeutics operates a single integrated platform business model centered on its proprietary Nanopolymer Drug-Delivery System. The core platform enables pH-responsive encapsulation and release of biologic payloads, particularly cytokines for cancer immunotherapy. The first pipeline product is IL-12 loaded nanopolymer micelles for solid tumor treatment, currently in preclinical stage, with additional polymer-drug conjugate cancer drugs in discovery.

Differentiator

Problem solved

Functional benefit

Products and services

  • IL-12 Loaded Nanopolymer Micelles Red Arrow's lead pipeline product: a polymer-drug conjugate that systemically delivers pro-inflammatory cytokine IL-12 via nanopolymer micelles to the solid tumor microenvironment, where the cytokine is released to recruit immune cells and induce cancer cell death. Intended for combination therapy with checkpoint inhibitors for solid tumor patients. Currently in preclinical stage.
  • Polymer-Drug Conjugate Cancer Drugs (Pipeline) Pipeline of polymer-drug conjugate cancer drugs developed using Red Arrow's proprietary nanopolymer platform for specific on-target on-tumor delivery and reduced on-target off-tumor toxicity. Follow-up pipeline efforts are currently in discovery phase.

Quantifiable outcome

  • Cytokine-loaded nanopolymer micelles can target the 80% of solid tumor patients who don't respond to checkpoint inhibitors

Companies that use Red Arrow Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Red Arrow Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Red Arrow Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • MassChallengecoreStrategic or Co-development Partner · 1 June 2023Accepted into U.S. Early Stage Growth Cohort program - prestigious startup accelerator focused on early stage companies.
  • UC Berkeley SkyDeckcoreStrategic or Co-development Partner · 1 November 2022Selected to join SkyDeck Accelerator Cohort Program with 1.5% acceptance rate worldwide. Dr. Takuya Miyazaki presented at Demo Day Berkeley SKYDECK in April 2023. Previous investment from SkyDeck included in total funding.
  • University of TokyocoreStrategic or Co-development PartnerSpin-out from University of Tokyo's Cabral Lab in 2021. Laboratory remains closely associated with the University of Tokyo. Technology developed by Prof. Dr. Horacio Cabral from University of Tokyo.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Red Arrow Therapeutics competitors and assessment

Company assessment

Direct peers

  • Selecta Biosciences: Developed synthetic nanoparticle immunotherapies including tolerogenic and immunogenic vaccines, with overlapping focus on programming immune responses using nanoparticle carriers.
  • Codiak BioSciences: Developed engineered exosome-based platforms for delivery of biologics including cytokines, the closest mechanistic analogue to Red Arrow's biologic-loaded nanocarrier approach.
  • Nanobiotix: Clinical-stage nanomedicine company developing nanoparticle-based cancer therapeutics. Directly comparable as a nanoparticle-platform oncology company, though at a more advanced clinical stage.
  • NanoCarrier Co., Ltd. Japanese specialty pharmaceutical company developing micellar nanoparticle drug delivery systems for cancer and other diseases. Closest geographic and technical peer in the Japanese nanomedicine ecosystem.
  • Merrimack Pharmaceuticals: Developed nanoliposomal oncology therapeutics (e.g., Onivyde) and built a pipeline around nanoparticle-encapsulated biologics for solid tumors, a comparable biologic-delivery strategy.
  • BIND Therapeutics: Pioneered targeted polymeric nanoparticle drug delivery for oncology, including programs delivering cytotoxics and other biologics. Closely aligned platform approach despite corporate restructuring.
  • CytImmune Sciences: Developed tumor-targeted gold nanoparticle delivery of TNF and other cytokines to solid tumors, directly comparable in payload (cytokines) and tumor-targeting mechanism.

Emerging players

  • Acuitas Therapeutics: Develops lipid nanoparticle (LNP) delivery technology used across nucleic-acid and biologic therapeutics, including for partners in oncology. Comparable as a delivery-platform peer at a more commercial stage.
  • PsiOxus Therapeutics: Developed tumor-targeted immunotherapies including cytokine-armed oncolytic viruses, a comparable strategy of localizing potent immunomodulators to the tumor microenvironment.

Broad incumbents

  • Arcturus Therapeutics: Clinical-stage biotech using lipid nanoparticle delivery platforms for nucleic-acid and protein-based therapeutics, with broader pipeline and manufacturing footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Red Arrow Therapeutics social profiles

Digital presence

Red Arrow Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Red Arrow Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Red Arrow Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Red Arrow Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Red Arrow Therapeutics

What does Red Arrow Therapeutics do?

Red Arrow Therapeutics develops a proprietary pH-responsive nanopolymer drug-delivery platform that encapsulates and releases biologics (including cytokines, small peptides, full-chain antibodies, and cationic/anionic proteins) specifically at tumor microenvironments. Its first pipeline asset delivers pro-inflammatory cytokine IL-12 for solid tumors and is in preclinical development, with additional polymer-drug conjugate cancer drugs in discovery.

Is Red Arrow Therapeutics a public or private company?

Red Arrow Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Red Arrow Therapeutics founded?

Red Arrow Therapeutics was founded in 2021. It employs 1 to 10 people.

Where is Red Arrow Therapeutics based?

Red Arrow Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Red Arrow Therapeutics make money?

One revenue line is on record: pharmaceutical Development.

Who are Red Arrow Therapeutics's main competitors?

Direct peers on record are Selecta Biosciences, Codiak BioSciences, Nanobiotix, NanoCarrier Co., Ltd., Merrimack Pharmaceuticals, BIND Therapeutics and CytImmune Sciences. Emerging players are Acuitas Therapeutics and PsiOxus Therapeutics. Arcturus Therapeutics is listed as a broad incumbent.

Does Red Arrow Therapeutics have an API?

No public API is recorded for Red Arrow Therapeutics.

What industry is Red Arrow Therapeutics in?

Red Arrow Therapeutics's product category is Oncology Nanomedicine / Drug Delivery. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Silicon Valley JournalsRed Arrow Therapeutics raised $4.5M Seed funding roundRed Arrow Therapeutics has closed a $4.5 million Seed Extension funding round from four institutional investors based in Japan, bringing its total capital raised to nearly $5.5 million. The company, a spinoff from the University of Tokyo specializing in pH-sensing nanomedicine for oncology, will use these funds to conduct preclinical studies on its lead compound and initiate manufacturing activities.FinSMEsRed Arrow Therapeutics Closes $4.5M Seed Extension FundingRed Arrow Therapeutics Inc. closed a $4.5 million Seed Extension funding round aimed at advancing its pH-sensing nanomedicine drug delivery technologies. The funding will be utilized to gather key preclinical data on the safety and efficacy of their lead compound and initiate manufacturing with external partners. This brings their total funding raised to nearly $5.5 million since their inception in 2021.PR NewswireRed Arrow Therapeutics Inc. closes $4.5M Seed Extension roundRed Arrow Therapeutics Inc. closed a $4.5 million Seed Extension financing round from four institutional investors in Japan, bringing its total cumulative funding to nearly $5.5 million. The capital will be used to obtain preclinical safety and efficacy data for its lead compound and initiate manufacturing collaborations.VC News DailyRed Arrow Therapeutics Nabs $4.5MRed Arrow Therapeutics has closed a $4.5 million Seed Extension funding round led by four institutional investors based in Japan. The Boston-headquartered biotech startup, founded in 2021, utilizes this capital to further develop its nanotechnology-based drug delivery systems. This investment highlights continued interest in early-stage biotech innovation despite the specific regional origin of the backers.RedarrowtxRed Arrow TheraputicRed Arrow Therapeutics has been selected to receive a grant of up to $45 million from Japan’s AMED over the next five years to support its drug discovery initiatives. The company is simultaneously seeking global investors for its next funding round, scheduled for late 2025 or early 2026. This development follows previous financial support from NEDO and a recent seed extension round involving University of Tokyo Edge Capital.